{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sevelamer+carbonate&page=2",
    "query": {
      "intervention": "Sevelamer carbonate",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sevelamer+carbonate&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sevelamer+carbonate&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T08:11:37.138Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00999037",
      "title": "FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Sevelamer Carbonate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Years to 21 Years"
      },
      "enrollment_count": 18,
      "start_date": "2009-10",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2023-05-31",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00999037"
    },
    {
      "nct_id": "NCT00967629",
      "title": "Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Sevelamer Carbonate",
          "type": "DRUG"
        },
        {
          "name": "Calcium Carbonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2009-06",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2011-11-18",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00967629"
    },
    {
      "nct_id": "NCT02346890",
      "title": "A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AZD1722",
          "type": "DRUG"
        },
        {
          "name": "Renvela",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardelyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2013-04",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02346890"
    },
    {
      "nct_id": "NCT01464190",
      "title": "A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease Requiring Chronic Dialysis"
      ],
      "interventions": [
        {
          "name": "PA21 (2.5 g tablet containing 500 mg iron)",
          "type": "DRUG"
        },
        {
          "name": "Sevelamer carbonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vifor Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 659,
      "start_date": "2011-09",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-04-01",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01464190"
    },
    {
      "nct_id": "NCT01543958",
      "title": "Sevelamer for Reducing Endotoxemia and Immune Activation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Sevelamer carbonate",
          "type": "DRUG"
        },
        {
          "name": "Sevelamer carbonate",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2011-11",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2018-10-11",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543958"
    },
    {
      "nct_id": "NCT01324128",
      "title": "A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease Requiring Chronic Dialysis"
      ],
      "interventions": [
        {
          "name": "PA21 (2.5 g tablet containing 500 mg iron)",
          "type": "DRUG"
        },
        {
          "name": "Sevelamer carbonate",
          "type": "DRUG"
        },
        {
          "name": "PA21-1 (1.25 g tablet containing 250 mg iron)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vifor Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1059,
      "start_date": "2011-03",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2014-04-24",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01324128"
    },
    {
      "nct_id": "NCT04485039",
      "title": "Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "Tecovirimat",
          "type": "DRUG"
        },
        {
          "name": "sevelamer carbonate oral tablet",
          "type": "DRUG"
        },
        {
          "name": "sucroferric oxyhydroxide chewable tablet",
          "type": "DRUG"
        },
        {
          "name": "calcium acetate oral tablet",
          "type": "DRUG"
        },
        {
          "name": "Lanthanum Carbonate Chewable Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SIGA Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 44,
      "start_date": "2022-06-08",
      "completion_date": "2023-04-23",
      "has_results": true,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04485039"
    },
    {
      "nct_id": "NCT00785629",
      "title": "A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Calcium acetate",
          "type": "DRUG"
        },
        {
          "name": "Lanthanum Carbonate",
          "type": "DRUG"
        },
        {
          "name": "Sevelamer Carbonate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denver Nephrologists, P.C.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2009-02",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2012-10-30",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00785629"
    },
    {
      "nct_id": "NCT01191762",
      "title": "Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperparathyroidism",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "sevelamer carbonate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kenneth R. Phelps, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-04",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-11-01",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 1,
      "location_summary": "Albany, New York",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01191762"
    },
    {
      "nct_id": "NCT03824587",
      "title": "Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hyperphosphatemia"
      ],
      "interventions": [
        {
          "name": "Tenapanor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Phosphate Binder Agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardelyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 236,
      "start_date": "2019-02-28",
      "completion_date": "2019-07-17",
      "has_results": true,
      "last_update_posted_date": "2023-03-06",
      "last_synced_at": "2026-10-02T08:11:37.138Z",
      "location_count": 48,
      "location_summary": "Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Lynwood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03824587"
    }
  ]
}